- Onyx Pharmaceuticals (NASDAQ:ONXX) has reportedly provided data from the Phase III trial of its blood-cancer drug Kyprolis to Amgen (NASDAQ:AMGN) and other potential acquirers, removing a stumbling block that had caused talks to stall.
- Amgen is in advanced negotiations to buy Onyx for $9.5B and had asked for the information to better assess the medicine, which is seen as a potential blockbuster, while AstraZeneca (NYSE:AZN) has also held discussions about a deal.
- Onyx had been reluctant to provide the data, as the trial of Kyprolis is still ongoing.